Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib and Rituximab in Steroid Refractory AIHA and CLL
NCT03827603Phase 2Unknown
- Start
- Feb 2017
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib in warm autoimmune hemolytic anemia (wAIHA) and pure red cell aplasia (PRCA). Primary endpoint: Overall Response Rate at 3 months. Status: unknown.
02
Drugs
ibrutinib
03
Conditions
warm autoimmune hemolytic anemia (wAIHA)pure red cell aplasia (PRCA)
Beyond the preview
Go deeper on NCT03827603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03827603.